Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OCUL 
Ocular Therapeutix Inc (OCUL)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2025: OCUL (5-star) is a STRONG-BUY. BUY since 73 days. Simulated Profits (50.24%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $17.75
1 Year Target Price $17.75
| 6 | Strong Buy |
| 6 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 212.75% | Avg. Invested days 47 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/18/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.12B USD | Price to earnings Ratio - | 1Y Target Price 17.75 |
Price to earnings Ratio - | 1Y Target Price 17.75 | ||
Volume (30-day avg) 12 | Beta 1.5 | 52 Weeks Range 5.79 - 13.85 | Updated Date 09/18/2025 |
52 Weeks Range 5.79 - 13.85 | Updated Date 09/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -502.57% |
Management Effectiveness
Return on Assets (TTM) -31.14% | Return on Equity (TTM) -63.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1802456863 | Price to Sales(TTM) 37.35 |
Enterprise Value 1802456863 | Price to Sales(TTM) 37.35 | ||
Enterprise Value to Revenue 31.81 | Enterprise Value to EBITDA -6.06 | Shares Outstanding 173995221 | Shares Floating 145237291 |
Shares Outstanding 173995221 | Shares Floating 145237291 | ||
Percent Insiders 3.33 | Percent Institutions 90.81 |
Upturn AI SWOT
Ocular Therapeutix Inc
Company Overview
History and Background
Ocular Therapeutix, Inc. was founded in 2006. It focuses on the development and commercialization of ophthalmic therapeutics using its proprietary bioresorbable hydrogel platform technology. The company has evolved from a research-focused entity to a commercial-stage company with FDA-approved products.
Core Business Areas
- Commercial Products: Focuses on sales and marketing of DEXTENZA, its FDA-approved product for treating ocular pain following ophthalmic surgery and allergic conjunctivitis.
- Pipeline Products: Developing a pipeline of sustained-release products for various eye conditions, including glaucoma, wet AMD, and dry AMD.
- Drug Delivery Technology: Utilizes proprietary bioresorbable hydrogel platform to deliver drugs directly to the eye.
Leadership and Structure
The leadership team consists of key executives in areas such as CEO, CFO, CSO, and CMO. The organizational structure includes departments for research and development, clinical operations, manufacturing, commercial operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- DEXTENZA: DEXTENZA is an FDA-approved corticosteroid insert for intracanalicular use in the treatment of ocular inflammation and pain following ophthalmic surgery and allergic conjunctivitis. Market share is difficult to ascertain precisely, but it competes with traditional steroid eye drops. Competitors include Alcon, Bausch + Lomb, and Novartis.
- PAXTRAVA: PAXTRAVA is an FDA-approved ophthalmic product for the treatment of ocular inflammation and pain following ophthalmic surgery and allergic conjunctivitis. Market share is difficult to ascertain precisely, but it competes with traditional steroid eye drops. Competitors include Alcon, Bausch + Lomb, and Novartis.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical industry is driven by the aging population, increasing prevalence of eye diseases, and technological advancements in drug delivery. The market is highly competitive, with numerous companies developing and commercializing novel treatments.
Positioning
Ocular Therapeutix is positioned as an innovator in sustained-release ophthalmic therapeutics. Its bioresorbable hydrogel technology offers a potential advantage over traditional eye drops, requiring less frequent administration. However, they are still a small player compared to bigger pharmaceutical companies.
Total Addressable Market (TAM)
The global ophthalmic market is estimated at over $40 billion. Ocular Therapeutix targets segments within this market with its pipeline. DEXTENZA addresses the post-surgical pain and inflammation market and the ocular allergic conjuctivitis market, and their pipeline will expand their TAM
Upturn SWOT Analysis
Strengths
- Proprietary bioresorbable hydrogel technology
- FDA-approved product (DEXTENZA)
- Strong pipeline of product candidates
- Targeted Drug Delivery
- Intellectual Property
Weaknesses
- Limited commercial infrastructure compared to larger competitors
- Reliance on a single approved product for revenue
- High R&D expenses
- Requires additional capital to fund ongoing operations
Opportunities
- Expansion of DEXTENZA's indications
- Partnerships with larger pharmaceutical companies
- Development of new ophthalmic therapeutics
- Further clinical validation of platform technology
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Pricing pressure from payers
- Generic entry or new alternative technologies
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- NVS
- BHC
Competitive Landscape
Ocular Therapeutix's strength lies in its innovative drug delivery technology. However, it faces intense competition from larger, well-established pharmaceutical companies with greater resources and broader product portfolios. Differentiation and strategic partnerships are critical for their success.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is related to increasing sales of DEXTENZA and progressing their product pipeline.
Future Projections: Future projections depend on the success of ongoing clinical trials and commercialization efforts.
Recent Initiatives: Recent initiatives include expanding the DEXTENZA label into new areas like ocular allergic conjuctivitis, partnering to develop sustained-release formulations, and advancing their pipeline of products for retinal diseases.
Summary
Ocular Therapeutix is a small pharmaceutical company with an innovative drug delivery platform. Its strength lies in DEXTENZA and its pipeline, but its limited commercial infrastructure poses challenges. Success depends on clinical trial outcomes and strategic partnerships. Competition in the ophthalmic market is fierce, requiring constant innovation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share estimates are approximate and may vary. Financial data is not available and requires API real time access.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ocular Therapeutix Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2014-07-25 | Executive Chairman, President & CEO Dr. Pravin U. Dugel M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 274 | Website https://www.ocutx.com |
Full time employees 274 | Website https://www.ocutx.com | ||
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.